Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
Brand Name :
Synonyms :
Class :
It is a drug that enhances the activity of the CFTR
It is prescribed for the treatment of cystic fibrosis (CF) in individuals aged two years and older who carry a single mutation in the CFTR gene that demonstrates responsiveness to ivacaftor, as confirmed by clinical and/or in vitro assay data
In cases where the patient's genetic profile is unknown, it is advised to employ an FDA-cleared CF mutation test for the identification of a CFTR mutation
Subsequent verification through bi-directional sequencing should be conducted as per the recommendations outlined in the mutation test instructions for use
For adults and pediatric patients aged six years and above, the recommended dosage is one 150 mg tablet via oral administration two times per day alongside a meal containing fat
Dose Adjustments
Limited data is available
For pediatrics who are between 1 month and two months with more than 3 kg weight, the dose recommended is 5.8 mg packet (oral granules) via oral administration two times per day
For pediatrics who are between 2 months and four months with more than 3 kg weight, the dose recommended is 13.4 mg packet (oral granules) via oral administration two times per day
For pediatrics who are between 4 months and six months with more than 5 kg weight, the dose recommended is 25 mg packet (oral granules) via oral administration two times per day
Pediatrics who are between 6 months and six years old with a weight between 5 and 7 kg, 7 and 14 kg, and more than 14 kg, the dose recommended is 25 mg, 50 mg, and 75 mg packet (oral granules) via oral administration two times per day
For pediatrics who are six years and above, the dose recommended is 150 mg via oral administration two times per day
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
nafcillin will decrease the effect of action of ivacaftor by affecting enzyme CYP3A4 metabolism.
the effect of lumacaftor/ivacaftor is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivacaftor 
it may enhance the metabolism when combined with oxcarbazepine
the coadministration of abatacept with ivacaftor has the potential to enhance the metabolism of ivacaftor
when combined with ivacaftor, there is a possibility of an increased serum concentration of abiraterone
the serum concentration of abrocitinib can be elevated when combined with ivacaftor
the serum concentration of acalabrutinib may increase when combined with ivacaftor
the serum concentration of acetaminophen can be increased when combined with ivacaftor
when combined with ivacaftor, there is a potential for an increased serum concentration of acetohexamide
the coadministration of zimelidine with ivacaftor may result in a reduction in the metabolism of ivacaftor
the serum concentration of zolpidem may be heightened when used in combination with ivacaftor
when combined with ivacaftor, there can be an increase in the serum concentration of zopiclone
when ivacaftor is used with other medications, the serum levels of zileuton may rise
the serum concentration of zotepine can be raised when combined with ivacaftor
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
fedratinib increases the effect of ivacaftor by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
idelalisib increases the effect or level of ivacaftor by altering the intestinal/hepatic CYP3A4 metabolism
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
May reduce the serum concentration of montelukast
May reduce the serum concentration of zafirlukast
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
when combined with abametapir, there may be an increase in the serum concentration of ivacaftor
the serum concentration of abemaciclib may experience an increase when combined with ivacaftor
when combined with ivacaftor, there may be an increase in the serum concentration of acenocoumarol
when ivacaftor is used with other medications, the serum levels of zileuton may rise
when combined with ziprasidone, there may be a decrease in the metabolism of ivacaftor
the serum concentration of zonisamide can be raised when combined with ivacaftor
the serum concentration of zotepine can experience an increase when combined with ivacaftor
when combined with ivacaftor, there is potential for an increased serum concentration of zuclopenthixol
when combined with ivacaftor, there is a possibility of an increased serum concentration of abiraterone
the serum concentration of acetaminophen can be increased when combined with ivacaftor
when combined with ivacaftor, there is a potential for an increased serum concentration of acetohexamide
the serum concentration of zolpidem may be heightened when used in combination with ivacaftor
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
